Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Offices

Turk, FIN
Tykistökatu 6
Turk, FI-20520, FIN

People

President and CEO
Board Member
Chairman
Chairman

Acquisitions

Total$122M
Neurelis, 6/2013
Synosia Therapeutics, 1/2011 $122M

Funding

TOTAL $144M
FUNDING TOTAL $144M
Grant, 6/2013
$144M

Tags

Biotie Therapies

Biotie is a specialized drug development company focused on central nervous system and inflammatory diseases. It has several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie’s products address diseases with high unmet medical need and significant market potential, including addiction and a broad range of inflammatory conditions such as rheumatoid arthritis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S.

Recent Milestones

Videos

Screenshots

Sources

  1. Biotie Purchases Option to Acquire Neurelis, Inc. (sys-con.com) [edit]
  2. Biotie buys CNS developer Synosia in $121.5M deal Read more: Biotie buys CNS developer Synosia in $121.5M deal - FierceBiotech http://www.fiercebiotech.com/story/biotie-buys-cns-developer-synosia-1215m-deal/2011-01-11?utm_medium=rss&utm_source=rss#ixzz1A (fiercebiotech.com) [edit]
  3. SEC (sec.gov) [edit]
Edit This Page
Last Edited 2/19/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy